Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2025 | June 05, 2025 |
| PFIZER INCPFE · Entity 2863 | Director | April 23, 2015 | April 24, 2015 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 03, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,886,576 |
Reported balance
After 2025-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 6,037 · Balance 1,886,576 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,037 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.93 · Expires 2035-06-03 | Direct | 18,111 |
Reported balance
After 2025-06-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-03 · Grant · Acquired 18,111 · Balance 18,111 F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 1 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 78,848 F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 2 | 79,173 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 79,173 F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 3 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 78,848 F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,037 unvested RSUs.
F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
PFIZER INC
Report date April 23, 2015 · Filed April 24, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,099.964 |
Reported balance
After 2015-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2015-04-23 · Grant · Acquired 4,595.588 · Balance 29,099.964 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,434 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 165 · Balance 2,434 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $725.89 · Expires 2033-01-03 | Direct | 1,929 |
Reported balance
After 2023-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-03 · Grant · Acquired 1,929 · Balance 1,929 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,250 | $273.67 | $1,163,097.50 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 4,250 | $273.67 | $1,163,097.50 |
DisclosureSEC source: 0001708138-21-000080 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 27,245 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · derivative · entry 8 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,245 shares Expires 2029-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option were fully vested and exercisable. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · derivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,830 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 100% of the shares subject to the option were fully vested and exercisable. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionStock Option (right to buy) · Derivative | 39,303 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · derivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,862 Underlying: Common Stock · 39,303 shares Expires 2027-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 700 | $71.06 | $49,744.10 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,544,370 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.02 to $71.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 93,678 | $70.35 | $6,589,778.91 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,545,070 F2 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.965 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 27,245 | $19.50 | $531,277.50 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,638,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 27,830 | $18.92 | $526,543.60 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,611,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 21:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | Exercise / conversionCommon Stock | 39,303 | $18.00 | $707,454.00 |
DisclosureSEC source: 0001209191-21-038978 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,583,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,074 restricted stock units. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 6,222 | $0.00 Strike: $63.76 | $0.00 |
DisclosureSEC source: 0001209191-21-038393 · doc4.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,222 Underlying: Common Stock · 6,222 shares Expires 2031-06-02 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:37 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 2,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038393 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,544,370 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 24, 2021 Filed May 25, 2021 00:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 8,806 | $60.03 | $528,580.15 |
DisclosureSEC source: 0001209191-21-035548 · doc4.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,542,296 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.135 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| May 21, 2021 Filed May 25, 2021 00:05 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 37,957 | $60.13 | $2,282,468.28 |
DisclosureSEC source: 0001209191-21-035548 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,551,102 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.67 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 98 | $61.20 | $5,997.60 |
DisclosureSEC source: 0001209191-21-030304 · doc4.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,589,059 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:14 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,139 | $60.08 | $188,591.12 |
DisclosureSEC source: 0001209191-21-030304 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,589,157 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.00 to $60.45 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,184 | $57.60 | $356,167.48 |
DisclosureSEC source: 0001209191-21-025119 · doc4.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,592,296 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.23 to $58.095 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 29,593 | $56.91 | $1,684,019.26 |
DisclosureSEC source: 0001209191-21-025119 · doc4.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,598,480 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.23 to $57.22 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:10 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,223 | $55.61 | $790,884.14 |
DisclosureSEC source: 0001209191-21-025119 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,628,073 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.22 to $56.21 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: Includes 3,253 restricted stock units. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,031 | $71.35 | $73,562.88 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,642,296 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.68 to $71.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 3,482 | $69.59 | $242,308.90 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,643,327 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.23 to $69.96 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 6,011 | $68.50 | $411,777.54 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,646,809 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $68.155 to $69.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 14,945 | $67.57 | $1,009,833.65 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,652,820 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $67.155 to $68.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,316 | $66.55 | $1,219,003.06 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,667,765 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $66.155 to $67.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 37,445 | $65.63 | $2,457,665.13 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,686,081 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $65.145 to $66.14 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:20 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 18,770 | $64.36 | $1,208,055.97 |
DisclosureSEC source: 0001209191-21-016855 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,723,526 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $64.08 to $65.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F3 · balance_after: The Reporting Person reported a prior award of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 3,253 previously reported restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,613 | $0.00 Strike: $482.68 | $0.00 |
DisclosureSEC source: 0001708138-21-000009 · edgardoc.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,613 Underlying: Common Stock · 3,613 shares Expires 2031-01-04 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 248 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-21-000009 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 16, 2020 Filed Jun 19, 2020 01:41 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 400,000 | $26.10 | $10,440,000.00 |
DisclosureSEC source: 0001209191-20-037764 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,739,043 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:00 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantRestricted Stock Units · Derivative | 3,253 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034767 · doc4.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,253 Underlying: Common Stock · 3,253 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F3 · derivative.expiration_date: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:00 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 15,183 | $0.00 Strike: $28.82 | $0.00 |
DisclosureSEC source: 0001209191-20-034767 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,183 Underlying: Common Stock · 15,183 shares Expires 2030-06-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $177.82 | $0.00 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · derivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $566.01 | $56,601.00 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · nonDerivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830 Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 900 | $565.35 | $508,815.00 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930 F4 · price: Represents volume-weighted average price of sales of 900 shares of Company stock on May 6, 2020 at prices ranging from $565.00 to $565.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 6, 2020 at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,600 | $564.45 | $3,725,370.00 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,830 F3 · price: Represents volume-weighted average price of sales of 6,600 shares of Company stock on May 6, 2020 at prices ranging from $564.00 to $564.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 6, 2020 at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6,375 | $563.45 | $3,591,993.75 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,430 F2 · price: Represents volume-weighted average price of sales of 6,375 shares of Company stock on May 6, 2020 at prices ranging from $563.00 to $563.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 6, 2020 at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,025 | $562.65 | $576,716.25 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,805 F1 · price: Represents volume-weighted average price of sales of 1,025 shares of Company stock on May 6, 2020 at prices ranging from $562.12 to $562.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 6, 2020 at each separate price. Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 15,000 | $177.82 | $2,667,300.00 |
DisclosureSEC source: 0001708138-20-000051 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $57.11 | $0.00 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · derivative · entry 8 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 9,279 | $0.00 Strike: $50.91 | $0.00 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · derivative · entry 7 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,279 shares Expires 2021-11-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 7,842 | $400.16 | $3,138,054.72 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · nonDerivative · entry 6 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830 F4 · price: Represents volume-weighted average price of sales of 7,842 shares of Company stock on February 13, 2020 at prices ranging from $400.02 to $400.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $399.41 | $319,528.00 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · nonDerivative · entry 5 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,672 F3 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on February 13, 2020 at prices ranging from $399.00 to $399.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 637 | $398.71 | $253,978.27 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · nonDerivative · entry 4 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,472 F2 · price: Represents volume-weighted average price of sales of 637 shares of Company stock on February 13, 2020 at prices ranging from $398.39 to $398.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 9,279 | $50.91 | $472,393.89 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · nonDerivative · entry 3 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5,000 | $400.03 | $2,000,150.00 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · nonDerivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830 F1 · price: Represents volume-weighted average price of sales of 5,000 shares of Company stock on February 13, 2020 at prices ranging from $400.00 to $400.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $57.11 | $285,550.00 |
DisclosureSEC source: 0001237899-20-000010 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,361 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001708138-20-000010 · edgardoc.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,361 Underlying: Common Stock · 4,361 shares Expires 2030-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-20-000010 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,830 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 30, 2019 Filed May 31, 2019 22:38 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,245 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-19-033740 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,245 Underlying: Common Stock · 27,245 shares Expires 2029-05-29 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 3,784 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001708138-19-000004 · edgardoc.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,784 Underlying: Common Stock · 3,784 shares Expires 2029-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.